Mathieu Quesnel-Vallieres

RNA/cancer postdoctoral researcher with @KristenWLynch1 and @YosephBarash at @PennMedicine
@SRC_CRS SNGS scholar
MOVED TO MASTODON @[email protected]

[Mathieu Quesnel-Vallieres @RNA_Ken]

Nouveau labo!
Je cherche des étudiant(e)s gradué(e)s voulant travailler dans le domaine de l'épissage de l'ARN en #cancer et #immunologie.

New lab!
I'm looking for grad students interested in #RNAsplicing in #cancer and #immunology

https://t.co/BwcE57iEwh

@jrRNAscientists

[Lars Juhl Jensen @larsjuhljensen]

Oops I did it again: A single, searchable, sortable, spreadsheet of all presentations at #ISMBECCB2023 https://t.co/106jgmmcIP
Have fun planning your conference!

[Mathieu Quesnel-Vallieres @RNA_Ken]

@ABG_Asso

[Mathieu Quesnel-Vallieres @RNA_Ken]

Nouveau labo!
Je cherche des étudiant(e)s gradué(e)s voulant travailler dans le domaine de l'épissage de l'ARN en #cancer et #immunologie.

New lab!
I'm looking for grad students interested in #RNAsplicing in #cancer and #immunology

https://t.co/BwcE57iEwh

@jrRNAscientists

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
Reminder of our upcoming online journal club tomorrow, May 2 at 15:30GMT/11:30EDT/8:30PT.

We will be discussing RNA structural switches discovery with 1st author khorms57

Register: https://t.co/Dye0BzBaNC

RNASociety
iscb
https://t.co/1Uwsi9Nzmx

[Mathieu Quesnel-Vallieres @RNA_Ken]

May:
https://t.co/mqhQNjhhLL
https://t.co/iRso04UWYd (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
Our sister journals Dev_journal
J_Cell_Sci J_Exp_Biol & DMM_Journal offer Travelling Fellowships of up to £3,000 to #biology #PhD students & #Postdocs wishing to make collaborative visits to other laboratories.

Next application deadline is 5 (1/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

switches.
https://t.co/EG0DAvOcLj

Free registration: https://t.co/4iA4rbCiOu

iscb RNASociety
https://t.co/xsoWjLKt8a (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
Thrilled to announce our upcoming journal club, May 2, 11:30am EDT (15:30GMT).

Dr. Matvei Khoroshkin, postdoc in genophoria lab at UCSF, will present results from their preprint on the discovery of RNA structural (1/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

exactly why the reputation of #journalism everywhere has been dragged through the mud. You are all simply puppets if you cannot create, support and / or foster a framework that supports journalistic freedom and integrity.
https://t.co/3SjJbSJoFK (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
#NPR should run their own #Mastodon instance as should every other serious news outfit. This bullshit where supposedly serious news organizations should have to capitulate to the whims of some narcissistic billionaire or corrupt government is (1/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

prospects, and quality of life

https://t.co/25tkxquSW1 (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

The NIH will be taking comments from the postdoc community over the next few days. Topics of high importance are on the agenda:

- Role, duration, structure, and value of the postdoc
- International trainee concerns
- Compensation and benefits
- Job security, career (1/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

#ONpoli #HamOnt #InducedTravel #InducedDemand

https://t.co/fnTI92NQgW
https://t.co/fVATf07kGV (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
A major escarpment access in #Hamilton is closing on short notice. Should you be worried about increased congestion because of detours? Surprisingly, probably not!

A thread about "traffic evaporation", the cool cousin of induced demand. (1/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

tag.

https://t.co/b0olBG8kib
https://t.co/fPEexlXo8T (3/3)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
Maybe you've heard about Trikafta, the 'miracle' drug that has transformed life for people with cystic fibrosis in North America and Europe? It costs $322,000 a year, and patients take it for life.
Turns out the drug isn't available for CF (1/3)

[Mathieu Quesnel-Vallieres @RNA_Ken]

patients anywhere in the developing world. And they say that's on purpose: that the maker, Vertex Pharmaceuticals, is deliberately obstructing access so as to be able to maintain that price (2/3)

[Mathieu Quesnel-Vallieres @RNA_Ken]

#lymphoma.

#FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment

https://t.co/rXpwRGl3v5
https://t.co/bzoDMU7cDa (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
My latest clinical pipeline column for NatureMedicine is out today.
It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody
for relapsed or refractory follicular (1/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

#journals.

https://t.co/RXvs5W0sJO
https://t.co/AxjYyWRLBK (2/2)

[Mathieu Quesnel-Vallieres @RNA_Ken]

RT @[email protected]
Just (re)discovered Casey Greene's super "preprint similarity search tool". It did a great job for our recent #preprint. It uses a language learning model to find like #publications to help you pick your target (1/2)